MY151439A - Medium-chain length fatty acids and glycerides as nephroprotection agents - Google Patents

Medium-chain length fatty acids and glycerides as nephroprotection agents

Info

Publication number: MY151439A
Authority: MY; Malaysia
Prior art keywords: nephroprotection; agents; medium; fatty acids; chain length
Prior art date: 2007-11-02

Application number

MYPI2010001861A

Other languages

English (en)

Inventor

Pichette Vincent

Leblond François

Lagraoui Mouna

Gagnon Lyne

Original Assignee

Prometic Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2008-11-03

Publication date

2014-05-30

2008-11-03 Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc

2014-05-30 Publication of MY151439A publication Critical patent/MY151439A/en

Links

239000003795 chemical substances by application Substances 0.000 title abstract 2
235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
229930195729 fatty acid Natural products 0.000 title abstract 2
239000000194 fatty acid Substances 0.000 title abstract 2
150000004665 fatty acids Chemical class 0.000 title abstract 2
125000005456 glyceride group Chemical group 0.000 title 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 2
208000020832 chronic kidney disease Diseases 0.000 abstract 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract 2
201000006370 kidney failure Diseases 0.000 abstract 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010061216 Infarction Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
239000005639 Lauric acid Substances 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000005784 autoimmunity Effects 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
239000002254 cytotoxic agent Substances 0.000 abstract 1
231100000599 cytotoxic agent Toxicity 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000028208 end stage renal disease Diseases 0.000 abstract 1
201000000523 end stage renal failure Diseases 0.000 abstract 1
230000001434 glomerular Effects 0.000 abstract 1
230000007574 infarction Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
238000013059 nephrectomy Methods 0.000 abstract 1
229960002446 octanoic acid Drugs 0.000 abstract 1
201000002793 renal fibrosis Diseases 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MYPI2010001861A 2007-11-02 2008-11-03 Medium-chain length fatty acids and glycerides as nephroprotection agents MY151439A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US98509407P	2007-11-02	2007-11-02

Publications (1)

Publication Number	Publication Date
MY151439A true MY151439A (en)	2014-05-30

Family

ID=40590499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI2010001861A MY151439A (en)	2007-11-02	2008-11-03	Medium-chain length fatty acids and glycerides as nephroprotection agents

Country Status (19)

Country	Link
US (1)	US9532962B2 (2)
EP (1)	EP2299998B1 (2)
JP (1)	JP5575655B2 (2)
KR (1)	KR101601987B1 (2)
CN (1)	CN101878028A (2)
AU (1)	AU2008318196B2 (2)
BR (1)	BRPI0818310A8 (2)
CA (1)	CA2704286C (2)
DK (1)	DK2299998T3 (2)
ES (1)	ES2664594T3 (2)
IL (1)	IL205362A (2)
MX (1)	MX338513B (2)
MY (1)	MY151439A (2)
NO (1)	NO2299998T3 (2)
NZ (1)	NZ584981A (2)
PT (1)	PT2299998T (2)
RU (1)	RU2519215C2 (2)
WO (1)	WO2009055933A1 (2)
ZA (1)	ZA201003030B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA022445B1 (ru)	2009-05-04	2016-01-29	Прометик Байосайенсиз Инк.	Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения
JP5706142B2 (ja) *	2010-04-28	2015-04-22	株式会社ファンケル	フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤
CN105997967B (zh) *	2010-10-27	2019-08-23	普罗米蒂克医药Smt有限公司	用于治疗癌症的化合物和组合物
CN103945840A (zh) *	2011-08-26	2014-07-23	国立大学法人大阪大学	糖尿病性心血管并发症的预防/治疗剂
KR20130023583A (ko) *	2011-08-29	2013-03-08	아주대학교산학협력단	파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물
CA2926599C (en)	2013-11-05	2021-05-04	Hill's Pet Nutrition, Inc.	Methods and compositions for improving kidney function
WO2017074266A1 (en) *	2015-10-30	2017-05-04	National University Of Singapore	Androgen biosynthesis inhibitor
CN105559071A (zh) *	2016-01-12	2016-05-11	刘保惠	一种适用于肾病的特殊医学用途配方食品及其制备方法
JP2017214342A (ja) *	2016-06-02	2017-12-07	日清オイリオグループ株式会社	排尿障害の予防用又は改善用組成物
MX2018015188A (es)	2016-06-08	2019-08-21	Sunregen Healthcare Ag	Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional.
CN110290786A (zh) *	2016-12-21	2019-09-27	普罗米蒂克医药Smt有限公司	用于预防或最小化上皮细胞-间充质细胞转换的方法和组合物
WO2019082912A1 (ja) *	2017-10-27	2019-05-02	学校法人北里研究所	慢性腎臓病の予防又は治療剤
WO2019155336A1 (en) *	2018-02-08	2019-08-15	Societe Des Produits Nestle S.A.	Mct-based nutrition blend for providing health benefits in companion animals
SG11202103011YA (en)	2018-10-11	2021-04-29	Basf As	Aromatic compounds and pharmaceutical uses thereof
CN109602012A (zh) *	2018-12-11	2019-04-12	李卫平	一种功能性低蛋白能量米及其制备方法
CN111184728B (zh) *	2020-02-20	2023-04-04	上海市儿童医院	海藻糖在肾病综合征中的应用
AU2023292465A1 (en) *	2022-06-15	2024-12-12	Hill's Pet Nutrition, Inc.	Pet food compositions
JP2024176004A (ja) *	2023-06-07	2024-12-19	リファインホールディングス株式会社	小胞体ストレス抑制剤、慢性腎臓病疾患予防改善剤および食品
CN118592613B (zh) *	2024-08-05	2025-01-07	杭州康源食品科技有限公司	中链脂肪酸混合结构脂在改善膳食诱导的糖脂代谢紊乱中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4602040A (en)	1983-04-18	1986-07-22	Warner-Lambert Company	Meclofenamic acid topical pharmaceutical composition
US4737384A (en) *	1985-11-01	1988-04-12	Allied Corporation	Deposition of thin films using supercritical fluids
CA2107581A1 (en)	1992-02-07	1993-08-08	Kiyoshi Sugiyama	Side-effect alleviant
US6689700B1 (en) *	1999-11-02	2004-02-10	University Of Massachusetts	Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates
US20030176500A1 (en)	2000-06-20	2003-09-18	Koen Molly	Medium chain fatty acids applicable as antimicrobial agents
IL142535A0 (en)	2001-04-11	2002-03-10	Yeda Res & Dev	Pharmaceutical compositions for the treatment of inflammation
JP5026655B2 (ja) *	2001-04-18	2012-09-12	プロメティック、バイオサイエンシーズ、インコーポレーテッド	好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
CN1827766B (zh)	2001-06-28	2010-08-25	徐荣祥	体外细胞的培养方法
RU2213570C2 (ru) *	2001-08-22	2003-10-10	Санкт-Петербургская Государственная Химико-Фармацевтическая Академия	ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ
US7030168B2 (en) *	2001-12-31	2006-04-18	Advanced Technology Materials, Inc.	Supercritical fluid-assisted deposition of materials on semiconductor substrates
US20040052836A1 (en)	2002-09-13	2004-03-18	Li Luk Chiu	Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
ATE419846T1 (de) *	2003-02-07	2009-01-15	Prometic Biosciences Inc	Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
PT1648851E (pt)	2003-07-25	2007-05-31	Prometic Biosciences Inc	Praparação de sais metálicos de ácidos gordos de cadeia média
EP1940379A4 (en)	2005-09-30	2009-05-13	Jackson H M Found Military Med	METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES

2008
- 2008-11-03 PT PT88451224T patent/PT2299998T/pt unknown
- 2008-11-03 KR KR1020107012064A patent/KR101601987B1/ko not_active Expired - Fee Related
- 2008-11-03 NO NO08845122A patent/NO2299998T3/no unknown
- 2008-11-03 MX MX2010004856A patent/MX338513B/es active IP Right Grant
- 2008-11-03 US US12/740,700 patent/US9532962B2/en not_active Expired - Fee Related
- 2008-11-03 MY MYPI2010001861A patent/MY151439A/en unknown
- 2008-11-03 RU RU2010122302/15A patent/RU2519215C2/ru active
- 2008-11-03 WO PCT/CA2008/001930 patent/WO2009055933A1/en not_active Ceased
- 2008-11-03 DK DK08845122.4T patent/DK2299998T3/en active
- 2008-11-03 NZ NZ584981A patent/NZ584981A/en not_active IP Right Cessation
- 2008-11-03 AU AU2008318196A patent/AU2008318196B2/en not_active Ceased
- 2008-11-03 CA CA2704286A patent/CA2704286C/en not_active Expired - Fee Related
- 2008-11-03 JP JP2010532389A patent/JP5575655B2/ja not_active Expired - Fee Related
- 2008-11-03 CN CN200880113724XA patent/CN101878028A/zh active Pending
- 2008-11-03 BR BRPI0818310A patent/BRPI0818310A8/pt not_active IP Right Cessation
- 2008-11-03 EP EP08845122.4A patent/EP2299998B1/en not_active Not-in-force
- 2008-11-03 ES ES08845122.4T patent/ES2664594T3/es active Active
2010
- 2010-04-26 IL IL205362A patent/IL205362A/en active IP Right Grant
- 2010-04-30 ZA ZA2010/03030A patent/ZA201003030B/en unknown

Also Published As

Publication number	Publication date
RU2010122302A (ru)	2011-12-10
ES2664594T3 (es)	2018-04-20
BRPI0818310A8 (pt)	2017-12-26
CA2704286C (en)	2016-08-23
RU2519215C2 (ru)	2014-06-10
JP5575655B2 (ja)	2014-08-20
IL205362A (en)	2015-01-29
US20100286269A1 (en)	2010-11-11
MX338513B (es)	2016-04-20
EP2299998B1 (en)	2018-01-03
BRPI0818310A2 (pt)	2017-10-10
ZA201003030B (en)	2011-02-23
JP2011502174A (ja)	2011-01-20
MX2010004856A (es)	2010-06-30
AU2008318196A1 (en)	2009-05-07
CA2704286A1 (en)	2009-05-07
NZ584981A (en)	2012-05-25
IL205362A0 (en)	2010-12-30
WO2009055933A1 (en)	2009-05-07
PT2299998T (pt)	2018-04-02
DK2299998T3 (en)	2018-03-26
EP2299998A4 (en)	2011-03-30
US9532962B2 (en)	2017-01-03
KR101601987B1 (ko)	2016-03-09
KR20100106958A (ko)	2010-10-04
EP2299998A1 (en)	2011-03-30
AU2008318196B2 (en)	2014-04-10
NO2299998T3 (2)	2018-06-02
CN101878028A (zh)	2010-11-03

Publication	Publication Date	Title
MY151439A (en)	2014-05-30	Medium-chain length fatty acids and glycerides as nephroprotection agents
WO2007073486A3 (en)	2008-07-10	Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2671584A3 (en)	2014-03-26	Compositions and methods for treating disorders associated with salt or fluid retention
WO2010005310A3 (en)	2010-04-15	Complement antagonists and uses thereof
WO2009109927A3 (en)	2010-02-25	Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2012019188A3 (en)	2012-06-14	Methods and compositions for the inhibition of fructokinase
CL2012002317A1 (es)	2012-11-30	Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
MX381737B (es)	2025-03-13	Agonistas de guanilato ciclasa útiles en la preparación de medicamentos para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EA200901155A1 (ru)	2010-02-26	Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
WO2010059253A3 (en)	2010-12-02	Methods and compositions for localized agent delivery
EP2355658A4 (en)	2012-03-28	NEW LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
EP2211913A4 (en)	2010-12-22	SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
WO2007101224A3 (en)	2008-10-16	Inhibitors of the unfolded protein response and methods for their use
EP2638903A4 (en)	2013-12-04	SUPPRESSOR FOR INCREASING THE BLOOD SUGAR MIRROR
JP2010222367A5 (2)	2011-08-25
IL193099A (en)	2016-04-21	Use of ferric citrate-containing preparations in the preparation of chronic kidney disease drugs
TR201901110T4 (tr)	2019-02-21	Empagliflozinin terapötik kullanımları.
WO2007138466A3 (en)	2009-04-23	Pharmaceutical compositions comprising meloxicam and tramadol combination
BRPI0922789A2 (pt)	2019-10-15	peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2012003051A (es)	2012-05-29	Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor.
ES2720954T3 (es)	2019-07-25	Formulaciones estabilizadas de estatina
CL2012002437A1 (es)	2012-12-07	Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
RU2014142066A (ru)	2016-05-10	Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
WO2012053013A3 (en)	2012-08-02	Pharmaceutical compositions of anti-acne agents
MX385881B (es)	2025-03-18	Forma de dosificacion de alivio prolongado